82
82P.F Pacira BioSciences Inc
- Market cap
- EUR 1.29B
- P/E
- 40.5x
- P/B
- 2.02x
- ROE
- 6.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 82P.F undervalued?
Graham number82P.F trades 90.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pacira BioSciences Inc fundamental analysis
No fundamental analysis for Pacira BioSciences Inc yet.
Pacira BioSciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pacira BioSciences Inc
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a …
Full company profilePacira BioSciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pacira BioSciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 276M | 287M | 337M | 421M | 421M | 542M | 667M | 675M | 701M | 726M | 729M |
| Gross Profit | 166M | 199M | 250M | 314M | 304M | 401M | 468M | 490M | 531M | 577M | 571M |
| Operating Income | -32.0M | -20.1M | 17.5M | 35.7M | 42.7M | 133M | 70.9M | 87.7M | 89.9M | 19.2M | 44.0M |
| EBITDA | - | -12.0M | 33.1M | 30.7M | 63.5M | 102M | 111M | 155M | 29.1M | 123M | 143M |
| Net Income | -37.9M | -42.6M | -471K | -11.0M | 146M | 42.0M | 15.9M | 42.0M | -99.6M | 7.03M | 48.1M |
| EPS | - | -1.05 | -0.01 | -0.26 | 3.33 | 0.94 | 0.35 | 0.90 | -2.15 | 0.17 | 1.21 |
| Balance Sheet | |||||||||||
| Total Assets | 391M | 628M | 689M | 831M | 1.27B | 2.08B | 1.68B | 1.57B | 1.55B | 1.26B | 1.20B |
| Total Liabilities | 172M | 349M | 368M | 476M | 655M | 1.34B | 906M | 704M | 775M | 572M | 490M |
| Shareholders' Equity | 219M | 279M | 321M | 355M | 620M | 730M | 775M | 870M | 778M | 693M | 712M |
| Cash & Short-term Investments | 35.9M | 54.1M | 133M | 78.2M | 100.0M | 586M | 104M | 153M | 277M | 159M | 247M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 33.5M | 17.8M | 48.9M | 70.5M | 77.0M | 126M | 145M | 155M | 189M | 152M | 178M |
| Capital Expenditure | 24.7M | 19.3M | 14.5M | 10.2M | 37.8M | 45.9M | 30.1M | 15.2M | 10.6M | 15.3M | 10.2M |
| Free Cash Flow | - | -1.48M | 34.4M | 60.4M | 39.2M | 79.9M | 115M | 139M | 179M | 137M | 167M |
| Ratios | |||||||||||
| ROE | -17.3% | -15.2% | -0.1% | -3.1% | 23.5% | 5.7% | 2.1% | 4.8% | -12.8% | 1.0% | 6.8% |
| ROA | -9.7% | -6.8% | -0.1% | -1.3% | 11.4% | 2.0% | 0.9% | 2.7% | -6.4% | 0.6% | 4.0% |
| Net Profit Margin | -13.7% | -14.9% | -0.1% | -2.6% | 34.6% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% | 6.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pacira BioSciences Inc dividends
Pacira BioSciences Inc has not paid dividends in the last 9 fiscal years.
Who owns Pacira BioSciences Inc
- Insiders 1.33%
- Institutions 98.67%
- Public & others 0.00%
- Shares outstanding 39.9M
- Free float 39.4M
Pacira BioSciences Inc company profile
- Company name
- Pacira BioSciences Inc
- Ticker
- 82P.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 825
- Fiscal year end
- December
- Address
- 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Phone
- 650 242 8052
- Website
- pacira.com
About Pacira BioSciences Inc
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Pacira BioSciences Inc management
10- Mr. Frank D. LeeCEO & Director · born 1968
- Mr. Shawn M. CrossChief Financial Officer · born 1968
- Ms. Kristen Williams Esq., J.D.Chief Administrative Officer & Secretary · born 1974
- Dr. Jonathan Slonin M.D.Chief Medical Officer · born 1975
- Mr. Brendan P. TeehanChief Commercial Officer · born 1969
- Ms. Lauren Bullaro RikerPrincipal Accounting Officer & Senior VP of Finance · born 1979
- Ms. Susan MescoHead of Investor Relations
- Mr. Anthony Molloy III, Esq.Chief Legal & Compliance Officer · born 1974
- Mr. Christopher C. YoungChief Manufacturing Officer · born 1972
- Ms. Krys Corbett Esq.Chief Business Officer